Five-year outcomes of premature infants randomized to high or standard loading dose caffeine.


Journal

Journal of perinatology : official journal of the California Perinatal Association
ISSN: 1476-5543
Titre abrégé: J Perinatol
Pays: United States
ID NLM: 8501884

Informations de publication

Date de publication:
05 2022
Historique:
received: 17 09 2021
accepted: 27 01 2022
revised: 05 01 2022
pubmed: 12 2 2022
medline: 14 5 2022
entrez: 11 2 2022
Statut: ppublish

Résumé

To examine 5-year outcomes in children enrolled in a pilot randomized controlled trial of a high loading dose of caffeine after preterm birth. Seventy-four very low birth weight neonates were randomized within the first 24 h of life to receive a high (80 mg/kg) or standard (20 mg/kg) loading dose of caffeine citrate. At 5 years of age, we conducted standardized neurodevelopmental tests and collected parent reports of child socioemotional problems. Seventy-four percent of survivors returned for follow up. Children obtained similar scores on neurodevelopmental and socioemotional evaluations. There was no difference in the incidence of any neurodevelopmental delay after controlling for confounding factors. Five-year follow up of a pilot trial of high loading dose caffeine citrate documented no profound impacts on childhood neurodevelopment or socioemotional outcome.

Identifiants

pubmed: 35145209
doi: 10.1038/s41372-022-01333-5
pii: 10.1038/s41372-022-01333-5
pmc: PMC9098661
mid: NIHMS1775944
doi:

Substances chimiques

Caffeine 3G6A5W338E

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

631-635

Subventions

Organisme : NINDS NIH HHS
ID : K02 NS089852
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH105179
Pays : United States
Organisme : NICHD NIH HHS
ID : K12 HD055931
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD057098
Pays : United States
Organisme : NICHD NIH HHS
ID : F30 HD105336
Pays : United States
Organisme : NICHD NIH HHS
ID : P50 HD103525
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH122735
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH113570
Pays : United States

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354:2112–21.
doi: 10.1056/NEJMoa054065
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357:1893–902.
doi: 10.1056/NEJMoa073679
Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307:275–82.
doi: 10.1001/jama.2011.2024
Schmidt B, Roberts RS, Anderson PJ, Asztalos EV, Costantini L, Davis PG, et al. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: an 11-year follow-up of the CAP randomized clinical trial. JAMA Pediatrics. 2017;171:564–72.
doi: 10.1001/jamapediatrics.2017.0238
Doyle LW, Cheong J, Hunt RW, Lee KJ, Thompson DK, Davis PG, et al. Caffeine and brain development in very preterm infants. Ann Neurol. 2010;68:734–42.
doi: 10.1002/ana.22098
Gray PH, Flenady VJ, Charles BG, Steer PA. Caffeine citrate for very preterm infants: effects on development, temperament and behaviour. J Paediatr Child Health. 2011;47:167–72.
doi: 10.1111/j.1440-1754.2010.01943.x
McPherson C, Neil JJ, Tjoeng TH, Pineda R, Inder TE. A pilot randomized trial of high-dose caffeine therapy in preterm infants. Pediatr Res. 2015;78:198–204.
doi: 10.1038/pr.2015.72
Crilly CJ, Haneuse S, Litt JS. Predicting the outcomes of preterm neonates beyond the neonatal intensive care unit: what are we missing? Pediatr Res. 2021;89:426–45.
Lean RE, Paul RA, Smyser TA, Smyser CD, Rogers CE. Social adversity and cognitive, language, and motor development of very preterm children from 2 to 5 years of age. J Pediatrics. 2018;203:177–84.
doi: 10.1016/j.jpeds.2018.07.110
Epstein NB, Baldwin LM, Bishop D. The McMaster family assessment device. J Marital Fam Ther. 1983;9:171–80.
doi: 10.1111/j.1752-0606.1983.tb01497.x
Wechsler D. WPPSI-III: Administration and Scoring Manual. San Antonio, TX: The Psychological Corporation; 2004.
Elliott CD. Differential ability scales. 2nd ed. San Antonio, TX: Harcourt Assessment; 2007.
Semel E, Wiig EH, Secord WA. Clinical evaluation of language fundamentalls preschool. 2nd ed. San Antonio, TX: Harcourt Assessment PsyCorp; 2004.
Henderson SE, Sugden DA, Barnett AL. Movement Assessment Battery for Children-2: Movement ABC-2: Examiner’s Manual. Sao Paulo: Pearson; 2007.
Nieto M, Ros L, Medina G, Ricarte JJ, Latorre JM. Assessing executive functions in preschoolers using shape school task. Front Psychol. 2016;7:1489.
doi: 10.3389/fpsyg.2016.01489
Achenbach TM, Roescorla LA. Manual for the ASEBA school-age forms & profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2001.
Constantino JN, Gruber CP. Social Responsiveness Scale, second edition (SRS-2). Los Angeles, CA: Western Psychological Services; 2012.
Pascal A, Govaert P, Oostra A, Naulaers G, Ortibus E, Van den Broeck C. Neurodevelopmental outcome in very preterm and very-low-birthweight infants born over the past decade: a meta-analytic review. Dev Med Child Neurol. 2018;60:342–55.
doi: 10.1111/dmcn.13675
Cheong JL, Spittle AJ, Burnett AC, Anderson PJ, Doyle LW. Have outcomes following extremely preterm birth improved over time? Semin Fetal Neonatal Med. 2020;25:101114.
doi: 10.1016/j.siny.2020.101114
Johnson S. Cognitive and behavioural outcomes following very preterm birth. Semin Fetal Neonatal Med. 2007;12:363–73.
doi: 10.1016/j.siny.2007.05.004
Lodha A, Entz R, Synnes A, Creighton D, Yusuf K, Lapointe A, et al. Early caffeine administration and neurodevelopmental outcomes in preterm infants. Pediatrics. 2019;143:e20181348.
Alhersh E, Abushanab D, Al-Shaibi S, Al-Badriyeh D. Caffeine for the treatment of apnea in the neonatal intensive care unit: a systematic overview of meta-analyses. Paediatr Drugs. 2020;22:399–408.
doi: 10.1007/s40272-020-00404-4
Tam EW, Rosenbluth G, Rogers EE, Ferriero DM, Glidden D, Goldstein RB, et al. Cerebellar hemorrhage on magnetic resonance imaging in preterm newborns associated with abnormal neurologic outcome. J Pediatrics. 2011;158:245–50.
doi: 10.1016/j.jpeds.2010.07.049
Volpe JJ. Cerebellum of the premature infant: rapidly developing, vulnerable, clinically important. J Child Neurol. 2009;24:1085–104.
doi: 10.1177/0883073809338067
Amaro CM, Bello JA, Jain D, Ramnath A, D’Ugard C, Vanbuskirk S, et al. Early caffeine and weaning from mechanical ventilation in preterm infants: a randomized, placebo-controlled trial. J Pediatrics. 2018;196:52–7.
doi: 10.1016/j.jpeds.2018.01.010

Auteurs

Christopher McPherson (C)

Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA. mcphersonc@wustl.edu.
Department of Pharmacy, St. Louis Children's Hospital, St. Louis, MO, USA. mcphersonc@wustl.edu.

Rachel E Lean (RE)

Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.

Peppar E P Cyr (PEP)

Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.

Terrie E Inder (TE)

Department of Pediatric Newborn Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Cynthia E Rogers (CE)

Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA.
Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.

Christopher D Smyser (CD)

Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Department of Radiology, Washington University in St. Louis, St. Louis, MO, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH